SCHEMBL2283700

SCHEMBL2283700

CC1(c2nc3cc(C(=O)N4CCC(c5cccnc5)C4)ccc3n2-c2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.49
MAPK7 Q13164 12/20 0.44
HPGD P15428 2/20 0.43
EPHX2 P34913 1/20 0.41
SPR P35270 1/20 0.40
HTR2B P41595 1/20 0.39
HSD11B1 P28845 1/20 0.39
PADI4 Q9UM07 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279229 0.98 NAMPT (0.48) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2281290 0.91 NAMPT (0.49) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2277906 0.89 NAMPT (0.52) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2279428 0.87 NAMPT (0.51) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2277871 0.87 NAMPT (0.51) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2281363 0.87 NAMPT (0.52) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2282725 0.87 HPGD (0.56) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2286262 0.87 NAMPT (0.50) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2280197 0.87 HPGD (0.53) NAMPTMAPK7HPGDEPHX2SPR
SCHEMBL2283714 0.87 NAMPT (0.51) NAMPTMAPK7HPGDEPHX2SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358202-B1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME (US) 2016-06-15 EP claimed
US-8470819-B2 Benzimidazole and aza-benzimidazole carboxamides MERCK SHARP & DOHME CORP. (US) 2013-06-25 US claimed
US-20110207750-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME LLC 2011-08-25 US claimed
EP-2358202-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES Merck Sharp & Dohme Corp. (US) 2011-08-24 EP claimed
WO-2010051245-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO claimed
EP-2358202-B1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME (US) 2016-06-15 EP disclosed
US-8470819-B2 Benzimidazole and aza-benzimidazole carboxamides MERCK SHARP & DOHME CORP. (US) 2013-06-25 US disclosed
US-20110207750-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME LLC 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207750-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES PAFAH1B3, PAFAH1B2, PAF1 NAMPT 1938/4885MAPK7 2084/4885HPGD 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.